Brought to you by 
Dublin-based generics company Actavis buys US spec pharma Forest Laboratories for $23.9bn
01 Jun 2021
Executive Summary
Dublin-based global generics company Actavis PLC acquired US specialty pharma Forest Laboratories Inc. in a cash and stock deal worth $23.9bn. Forest stockholders get $88.04 per share ($26.04 cash and 0.3306 Actavis shares (worth $62 based on the ten-day average)), a 29% premium.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Pulmonary
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dublin-based generics company Actavis buys US spec pharma Forest Laboratories for $23.9bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice